2.8.1 For tumor stage I–III: evaluation every 3 months for 2 years then every 6 months for 3 years then annually. CT scan of the chest every 6 months for 2 years then annually for 3 years.   2.8.2 Stage IV: evaluation every 2–3 months as clinically indicated. III. SMALL CELL LUNG CANCER  3.1

Stage I–III (Previously called limited stage):   3.1.1 Offer cisplatin/etoposide with radiation therapy then consolidate with two cycles of cisplatin/etoposide (EL-1). May substitute cisplatin with carboplatin in patients with neuropathy, renal dysfunction or hearing problem.   3.1.2 After definitive therapy with Complete Response (CR) or near CR offer prophylactic cranial irradiation (PCI) (EL-1).   3.1.3 For stage (T1-2 N0 confirmed by mediastinoscopy), offer surgical resection followed by chemotherapy, radiotherapy and prophylactic brain radiotherapy (EL-2).   3.1.4 Follow up and surveillance per Section see more 3.3.  3.2 STAGE IV (Previously Extensive Stage)   3.2.1 Offer cisplatin/etoposide or cisplatin/irinotecan x 6 cycles (EL-1).   3.2.2 After definitive therapy with evidence of response and good performance status offer PCI (EL-1).   3.2.3 For previously treated patients who relapsed in less than 6 months

from initial treatment, offer topotecan (EL-1) or cyclophosphamide, adriamycin and vincristin (CAV), or camptozar.   3.2.4 For relapse after six months from initial treatment, may use original regimen.   3.2.5 Follow up and surveillance per Section 3.3.  3.3 FOLLOW UP AND SURVEILLANCE   3.3.1 Evaluation includes: history and physical examination, Selleck SCH772984 laboratory

data and chest X-ray.   3.3.2 Stage I–III: evaluation every 3 months for 2 years then every 6 months for 3 years then annually. CT scan of the chest every 6 months for 2 years then annually for 3 years.   3.3.3 Stage IV: evaluation every 2–3 months as clinical indicated Full-size table Table options View in workspace Download as CSV “
“The management Vildagliptin of lung cancer is undergoing significant transition toward more personalized therapy that takes into account the histological features and molecular markers of the tumor in addition to clinical features such as smoking history, performance status and comorbidities. The 2012 Saudi Lung Cancer Guidelines incorporated emerging recommendations that have strong evidence and impact patient outcome. In this manuscript, we will highlight the major updates from the prior guidelines. The initial patient assessment is critical to determine and document 3 major variables, in addition to obtaining good history and perform physical examination. These variables are performance status (PS), smoking history and comorbidities. 1. Performance status: Historically, performance status is one of the most reliable prognostic factors in lung cancer. It dictated the management of the patients for many years.